Background Minocycline, a member of the tetracycline family, has a low risk of adverse effects and an ability to improve behavioral performance in humans with cognitive disruption. We performed a ...
The US National Institutes of Health unit National Eye Institute (NEI) has reported that a Phase II clinical trial of the drug minocycline for the treatment of dry age-related macular degeneration ...